Trial ID # | NCT03797326 |
Phase | II |
Drug Class | Angiogenesis Inhibitors: Multi-targeted RTK |
Drug Name | Lenvatinib |
Alternate Drug Names | MK-7902, Lenvima, ER-203492-00, E7080 |
Drugs in Trial | Lenvatinib, Pembrolizumab |
Eligible Participant | Advanced solid tumors |
Patients Enrolled | 31 ovarian; median 3 prior therapies; 25 Pt-R |
Therapy Setting | Recurrence |
Study Design | Open-Label, Non-randomized |
Endpoints | ORR, DCR, PFS, evaluated per RECIST |
Efficacy | ORR: 32% (n=31) Exploratory analysis, Pt-status, prior Bevacizumab: |
Clinically Significant Adverse Events | Serious AE: 1 death (hypovolemic shock) |
Conclusion | Lenvatinib+pembrolizumab demonstrates encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure |
Reference | Gonzales-Martin A et al. Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study. IGCS (2020) Plenary I, abstract 2 Gonzales-Martin A et al. Table from abstract Lwin Z et al. LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Annals Oncol (2020) 31 (suppl_4): abstract LBA41 |